These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8985818)

  • 41. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation.
    Castells L; Vargas V; Allende H; Bilbao I; Luis Lázaro J; Margarit C; Esteban R; Guardia J
    J Hepatol; 2005 Jul; 43(1):53-9. PubMed ID: 15876467
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: a multicentre, prospective study.
    Degos F; Pol S; Chaix ML; Laffitte V; Buffet C; Bernard PH; Degott C; Carnot F; Riffaud PC; Chevret S
    Nephrol Dial Transplant; 2001 May; 16(5):1017-23. PubMed ID: 11328909
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy.
    Koirala J; Gandotra SD; Rao S; Sangwan G; Mushtaq A; Htwe TH; Adamski A; Blessman D; Khardori NM
    J Viral Hepat; 2007 Nov; 14(11):782-7. PubMed ID: 17927614
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group.
    Keeffe EB; Hollinger FB
    Hepatology; 1997 Sep; 26(3 Suppl 1):101S-107S. PubMed ID: 9305673
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?
    Berardi S; Lodato F; Gramenzi A; D'Errico A; Lenzi M; Bontadini A; Morelli MC; Tamè MR; Piscaglia F; Biselli M; Sama C; Mazzella G; Pinna AD; Grazi G; Bernardi M; Andreone P
    Gut; 2007 Feb; 56(2):237-42. PubMed ID: 16798778
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.
    Samuel D; Bizollon T; Feray C; Roche B; Ahmed SN; Lemonnier C; Cohard M; Reynes M; Chevallier M; Ducerf C; Baulieux J; Geffner M; Albrecht JK; Bismuth H; Trepo C
    Gastroenterology; 2003 Mar; 124(3):642-50. PubMed ID: 12612903
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Two dose regimens of recombinant interferon-alpha-2b in chronic hepatitis C virus infection. Biochemistry, hepatitis C virus RNA, and liver histology as response indices.
    Bjøro K; Krarup H; Bell H; Christophersen P; Evensen S; Frøland SS; Laursen A; B vd Lippe B; Maeland A; Ranek L
    Scand J Gastroenterol; 1995 Nov; 30(11):1119-24. PubMed ID: 8578174
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.
    Myers RP; Benhamou Y; Bochet M; Thibault V; Mehri D; Poynard T
    AIDS; 2004 Jan; 18(1):75-9. PubMed ID: 15090832
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum.
    Ampurdanés S; Olmedo E; Maluenda MD; Forns X; López-Labrador FX; Costa J; Sánchez-Tapias JM; de Anta MT; Rodés J
    J Hepatol; 1996 Dec; 25(6):827-32. PubMed ID: 9007709
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interferon-alpha therapy in patients dually infected with hepatitis C virus and GB virus C/hepatitis G virus--virological response of HGV and pretreatment HGV viremia level.
    Orito E; Mizokami M; Yasuda K; Sugihara K; Nakamura M; Mukaide M; Ohba KI; Nakano T; Kato T; Kondo Y; Kumada T; Ueda R; Iino S
    J Hepatol; 1997 Oct; 27(4):603-12. PubMed ID: 9365035
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study.
    Barbaro G; Di Lorenzo G; Soldini M; Giancaspro G; Bellomo G; Belloni G; Grisorio B; Annese M; Bacca D; Francavilla R; Rizzo G; Barbarini G
    Am J Gastroenterol; 1998 Dec; 93(12):2445-51. PubMed ID: 9860407
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C.
    Carr C; Hollinger FB; Yoffe B; Wakil A; Phillips J; Bzowej N; Leung J; Mirro K; Poordad F; Moore DH; Gish RG
    Liver Int; 2007 Oct; 27(8):1111-8. PubMed ID: 17845540
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of acute hepatitis C with interferon alfa-2b.
    Jaeckel E; Cornberg M; Wedemeyer H; Santantonio T; Mayer J; Zankel M; Pastore G; Dietrich M; Trautwein C; Manns MP;
    N Engl J Med; 2001 Nov; 345(20):1452-7. PubMed ID: 11794193
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.
    McHutchison JG; Gordon SC; Schiff ER; Shiffman ML; Lee WM; Rustgi VK; Goodman ZD; Ling MH; Cort S; Albrecht JK
    N Engl J Med; 1998 Nov; 339(21):1485-92. PubMed ID: 9819446
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sarcoidosis after interferon therapy for chronic active hepatitis C.
    Teragawa H; Hondo T; Takahashi K; Watanabe H; Ohe H; Hattori N; Watanabe Y; Amano H; Hino F; Ohbayashi M; Urushihara T; Yonehara S
    Intern Med; 1996 Jan; 35(1):19-23. PubMed ID: 8652926
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy.
    Kurosaki M; Enomoto N; Murakami T; Sakuma I; Asahina Y; Yamamoto C; Ikeda T; Tozuka S; Izumi N; Marumo F; Sato C
    Hepatology; 1997 Mar; 25(3):750-3. PubMed ID: 9049230
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.
    Marcellin P; Boyer N; Gervais A; Martinot M; Pouteau M; Castelnau C; Kilani A; Areias J; Auperin A; Benhamou JP; Degott C; Erlinger S
    Ann Intern Med; 1997 Nov; 127(10):875-81. PubMed ID: 9382365
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pre-treatment with prednisolone does not improve the efficacy of subsequent alpha interferon therapy in chronic hepatitis C.
    Guilera M; Forns X; Torras X; Enríquez J; Coll S; Solà R; Morillas R; Planas R; Ampurdanès S; Soler M; Costa J; Sáiz JC; Sánchez-Tapias JM; Rodés J
    J Hepatol; 2000 Jul; 33(1):135-41. PubMed ID: 10905597
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effectiveness and tolerance of interferon-alpha 2b in the treatment of chronic hepatitis C in haemodialysis patients.
    Pol S; Thiers V; Carnot F; Zins B; Roméo R; Berthelot P; Bréchot C
    Nephrol Dial Transplant; 1996; 11 Suppl 4():58-61. PubMed ID: 8918758
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clearance of hepatitis C virus after living-donor liver transplantation in spite of residual viremia on end date of interferon therapy before transplantation.
    Ichikawa T; Nakao K; Hamasaki K; Honda T; Shibata H; Akahoshi M; Eguchi S; Takatsuki M; Kanematsu T; Eguchi K
    World J Gastroenterol; 2007 Aug; 13(30):4149-51. PubMed ID: 17696240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.